Evaxion A/S EVAX

EVAX Company Overview

Evaxion Biotech A/S, commonly referred to as Evaxion A/S and publicly traded on Nasdaq under the ticker EVAX, is a Denmark-based biotechnology company focused on the development of AI-powered immunotherapies and vaccines. The company operates within the biotechnology, oncology, and infectious disease sectors, using proprietary artificial intelligence platforms to identify and design therapeutic vaccine candidates. Its primary revenue sources historically have included research collaborations, grant funding, and capital raised through public markets, as the company remains in the clinical development stage and does not yet report material commercial product sales.

Evaxion’s core business centers on individualized and precision-based immunotherapies, particularly cancer vaccines targeting neoantigens and bacterial disease prevention technologies. The company’s proprietary AI platforms include PIONEER, EDEN, and RAVEN, which are designed to predict clinically relevant antigens and optimize vaccine development. Founded in Denmark in 2008, Evaxion evolved from an AI-focused biotechnology research company into a clinical-stage immunotherapy developer with multiple oncology and infectious disease programs. The company has positioned itself around the combination of machine learning and immunology, seeking to shorten vaccine discovery timelines and improve treatment specificity.